skip to Main Content

AIM-HI Portfolio Company Profile: Tvardi Therapeutics

  • July 29, 2020
  • Blog

Imran Alibhai, Ph.D., is the CEO of Tvardi Therapeutics, a biopharmaceutical company developing breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. The National Foundation for Cancer Research and AIM-HI Accelerator Fund have been early financial supporters of…

AIM-HI Portfolio Company Profile: InterLeukin Combinatorial Therapies

  • July 22, 2020
  • Blog

Paul Fisher, M.Ph., Ph.D., co-founded InterLeukin Combinatorial Therapies with hopes of developing a product that destabilizes and kills cancer cells. The Director of Virginia Commonwealth University’s Institute of Molecular Medicine, Fisher represents a world-class scientist with knowledge also of how…

Meet Rose Wang

  • July 10, 2020
  • Blog

Rose Wang is a serial entrepreneur who helps other individuals and teams—including female cancer researchers—start their own businesses and make them thrive. Wang is the founder of Binary Group, a consulting and business solutions firm. She also currently serves as Executive…

Meet Charlie Weatherspoon

The National Foundation for Cancer Research is a "special organization," says Charlie Weatherspoon, Co-founder and Chairman of the Board of the AIM-HI Accelerator Fund (AIM-HI), which has a strong relationship with NFCR. Weatherspoon contrasts the grassroots efforts at NFCR and…

Oncoheroes Biosciences and Super Sam Foundation Walking Together for Pediatric Cancer Heroes

Oncoheroes Biosciences, currently working on the clinical development of volasertib, a potential new drug for rhabdomyosarcoma patients, is honored to announce the receipt of funding from Super Sam Foundation, a pediatric cancer non-profit. Read more: https://oncoheroes.com/insights-news-1/2020/5/29/oncoheroes-biosciences-and-super-sam-foundation-walking-together-for-the-pediatric-cancer-heroes

Back To Top